PHAT Earnings

PHAT reported its FY2025Q3 earnings on 2025-10-30, showcasing a revenue of 49.50M against an estimate of 46.99M, resulting in a 5.34% surprise. The EPS was -0.15, surpassing the expected -0.4 by 62.5% . The stock experienced a -1.63% price change on the earnings day and a -0.3% change over the next five days, reflecting market reactions to the results.

Following PHAT's FY2025Q3 earnings announcement on 2025-10-30, the stock price moved by -1.63% on the day of the release. Over the subsequent five days, it saw a -0.30% change. Historically, PHAT's stock price tends to shift by an average of -0.25% in the 10 days leading up to earnings and +3.18% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PHAT’s annual revenue to reach 56.16M, while the EPS is projected at -0.39. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.1% and EPS estimates Revise Upward by 0.3% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PHAT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.1%, while EPS estimates moved Revise Upward by 0.3% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PHAT's stock price typically moves by -0.25% in the 10 days before its earnings and +3.18% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.39 and revenue of 56.16M.

The earnings call summary and Q&A session indicate positive sentiment. The company has strong revenue guidance for 2025, plans for profitability by 2026, and reduced cash usage. The Q&A revealed management's confidence in overcoming challenges, such as prescription growth and advertising cuts. The strategic focus on gastroenterology practices and the expected inflection point in sales suggest positive momentum. While there are some uncertainties, the overall outlook is optimistic, leading to a positive sentiment rating.